Who
David J. Matlin
Director
Company insider
Files Form 4 as: Director, Clene; Chief Financial Officer, TriSalus Life Sciences; Director and 10% owner, U.S. Well Services; 10% owner, Lonestar Resources US; Director, Flagstar Bancorp; 10% owner, Myos Rens Technology; Director and 10% owner, CalAtlantic Group; Director and 10% owner, Huntsman.
In numbers
- Trades disclosed
- 329
- Buys
- 43
- Sells
- 15
- Bought
- $557.0M
- Sold
- $3.3B
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 6 Aug 2007
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | CLNN CleneBiotechnology | SEC FORM 4 Code A | $1.4M434,451 at $3.28 | filing |
| 16 Sep 2026filed 18 Sep 2026 | CLNN CleneBiotechnology | SEC FORM 4 Code A | $1.4M434,451 at $3.28 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,230 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,230 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,659 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,659 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Code A | —28,201 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Code A | —23,065 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | TLSI TriSalus Life Sciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —56,403 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | TLSI TriSalus Life Sciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —56,403 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Code A | —28,201 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Code A | —23,065 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,372 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,372 at $0.00 | filing |
| 13 Jan 2026filed 13 Jan 2026 | CLNN CleneBiotechnology | SEC FORM 4 Bought | $217K33,333 at $6.50 | filing |
| 13 Jan 2026filed 13 Jan 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 | filing |
| 13 Jan 2026filed 13 Jan 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,333 | filing |
| 13 Jan 2026filed 13 Jan 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 | filing |
News
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSCLNN · manilatimes.net · 19 Oct 2026Head to Head Survey: Shineco (NASDAQ:SISI) vs. Clene (NASDAQ:CLNN)CLNN · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name David J. Matlin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.